Prime Medicine, Inc.
PRME- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001894562
No open-market purchases or sales by Prime Medicine, Inc. insiders were filed in the last 90 days; 187 institutions reported holding it in 13F filings for Q2 2026, worth $393.5M in total; ARK Invest is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Prime Medicine, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 122 | 3 | 116 | −3 |
| Shares | 68.9M | 5.19M | 68.7M | +5.01M (+7.9%) |
| Value | $354.0M | $26.7M | $265.9M | −$61.5M (−18.8%) |
3 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held Prime Medicine, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 5,266,775 | $20.4M | 0.00% |
| Walleye Capital LLC | 108,374 | $419.4K | 0.00% |
| Gsa Capital Partners LLP | 99,060 | $383.0K | 0.03% |
| SG Americas Securities, LLC | 46,982 | $182.0K | 0.00% |
| Verition Fund Management LLC | 38,545 | $149.2K | 0.00% |
| Levin Capital Strategies, L.P. | 30,000 | $116.1K | 0.01% |
| Renaissance Technologies LLC | 20,000 | $77.4K | 0.00% |
| Corsair Capital Management, L.P. | 20,000 | $77.4K | 0.02% |
| Pathstone Holdings, LLC | 14,370 | $55.6K | 0.00% |
| Intech Investment Management LLC | 14,102 | $54.6K | 0.00% |
| Paloma Partners Management Co | 11,587 | $44.8K | 0.00% |
| Acadian Asset Management LLC | 10,886 | $42.0K | 0.00% |
| Quadrant Capital Group LLC | 966 | $3.74K | 0.00% |
| Sterling Capital Management LLC | 58 | $224 | 0.00% |
| Federated Hermes, Inc. | 4 | $15 | 0.00% |
Sold out (18)
Institutions that held Prime Medicine, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Ensign Peak Advisors, Inc | 103,190 | $530.4K |
| Thrivent Financial for Lutherans | 62,093 | $319.0K |
| Royce & Associates LP | 60,999 | $313.5K |
| PDT Partners, LLC | 49,325 | $253.5K |
| Virtu Financial LLC | 42,741 | $220.0K |
| Wellington Management Group LLP | 37,646 | $193.5K |
| AQR Capital Management LLC | 34,268 | $176.1K |
| Susquehanna Portfolio Strategies, LLC | 29,247 | $150.3K |
| Cornercap Investment Counsel Inc | 28,923 | $148.7K |
| Green Alpha Advisors, LLC | 26,245 | $134.9K |
| Alpine Global Management, LLC | 17,373 | $89.3K |
| Principal Financial Group Inc | 12,187 | $62.6K |
| Balyasny Asset Management LLC | 12,101 | $62.2K |
| STRS Ohio | 10,000 | $51.4K |
| ORG Partners LLC | 5,270 | $28.9K |
| nVerses Capital, LLC | 3,500 | $18.0K |
| Group One Trading, L.P. | 1,975 | $10.2K |
| Avion Wealth | 79 | $0 |
Not filed for Q3 2024 yet (3)
Institutions that held Prime Medicine, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 5,110,418 | $26.3M |
| Susquehanna Fundamental Investments, LLC | 49,379 | $253.8K |
| Benjamin F. Edwards & Company, Inc. | 25,326 | $130.0K |